By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...
In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet rolled ...
Zacks Investment Research on MSN
Here's why you should retain DexCom stock in your portfolio
DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the ...
The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling. Dexcom said it traced sales of the ...
Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.
Through independent moderation by Vital Findings, council members reinforced that Dexcom remains a life-changing, essential ...
Continuous glucose monitoring may have a role for adults with type 2 diabetes who are not using insulin, according to results ...
Barchart on MSN
Is DexCom stock underperforming the Dow?
Valued at a market cap of $28 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that ...
Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a ...
DexCom says certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results